Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reltodecacog alfa
- Development stage
- Phase 3
- Lead developer
- VarmX
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
reltodecacog alfa (VMX-C001) is a modified recombinant human coagulation factor X (FX) zymogen being developed as a bypassing agent to restore blood coagulation in patients taking direct oral factor Xa (FXa) inhibitors (such as apixaban, rivaroxaban, and edoxaban) who experience severe bleeding or require urgent surgery. Developed by VarmX (a spin-off from Leiden University Medical Center) in collaboration with CSL, the protein is engineered with a modified sequence (inspired by snake venom) that renders it insensitive to inhibition by FXa direct oral anticoagulants (DOACs) while retaining its ability to be activated and participate in the coagulation cascade to generate thrombin.
- Other names
- modified recombinant human factor Xmodified recombinant human factor X zymogenrecombinant modified Factor Xreltodecag alfareltodecacog alfa
02
Targets
F5a (Coagulation Factor Va)F10 (Factor Xa)F2 (Thrombin)
Beyond the preview
Go deeper on reltodecacog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reltodecacog alfa.